Neumora Therapeutics, Inc. Common Stock (NMRA) has a negative trailing P/E of -1.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 14.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -68.72%, forward earnings yield 6.73%.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2020 | -24.9 | 0.00 | -26.16 | 0.00 | - |
| 2021 | -10.4 | -0.07 | -7.59 | 0.00 | - |
| 2022 | -18.9 | 0.42 | -5.53 | 0.00 | - |
| 2023 | -11.5 | -0.16 | 5.77 | 0.00 | - |
| 2024 | -6.9 | -2.58 | 5.89 | 0.00 | - |
| 2025 | -1.2 | 0.24 | 2.82 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2020 | $-0.65 | $0.00 | $-99.27M | - |
| 2021 | $-1.56 | $0.00 | $-237.31M | - |
| 2022 | $-0.86 | $0.00 | $-130.9M | - |
| 2023 | $-1.49 | $0.00 | $-235.93M | - |
| 2024 | $-1.53 | $0.00 | $-243.79M | - |
| 2025 | $-1.45 | $0.00 | $-236.93M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.98 | $-1.27 – $-0.62 | $625K | $625K – $625K | 7 |
| 2027 | $-0.90 | $-1.23 – $-0.46 | $5.54M | $5.38M – $5.7M | 6 |
| 2028 | $-0.84 | $-1.15 – $-0.32 | $62.38M | $62.38M – $62.38M | 8 |
| 2029 | $-0.50 | $-0.50 – $-0.50 | $207.37M | $207.37M – $207.37M | 6 |
| 2030 | $0.14 | $0.14 – $0.14 | $439.8M | $439.8M – $439.8M | 6 |
